iShares US Pharmaceuticals ETF
143 hedge funds and large institutions have $379M invested in iShares US Pharmaceuticals ETF in 2024 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 32 increasing their positions, 50 reducing their positions, and 14 closing their positions.
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
4% more funds holding
Funds holding: 137 → 143 (+6)
10% less capital invested
Capital invested by funds: $422M → $379M (-$42.3M)
36% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 50
146.55% less ownership
Funds ownership: 204.27% → 57.71% (-147%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWM
Accurate Wealth Management
Wesley Chapel,
Florida
|
+$7.72M |
| 2 |
VCM
Virtue Capital Management
Brentwood,
Tennessee
|
+$5.13M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3M |
| 4 |
SCA
Southern Capital Advisors
Jackson,
Tennessee
|
+$2.57M |
| 5 |
MFG
Merit Financial Group
Alpharetta,
Georgia
|
+$2.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$50.6M |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$11.4M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$8.17M |
| 4 |
RIG
RiverFront Investment Group
Richmond,
Virginia
|
-$7.02M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
-$5.63M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SW
151
SteelPeak Wealth
Woodland Hills,
California
| – | -$218K | -3,534 | Closed |
|
|
AWM
152
Angeles Wealth Management
Santa Monica,
California
| – | -$121K | -1,950 | Closed |
|
|
AC
153
AlphaCore Capital
La Jolla,
California
| – | -$55.6K | -900 | Closed |
|
|
VNA
154
Valley National Advisers
Bethlehem,
Pennsylvania
| – | -$22K | -360 | Closed |
|
|
TPCW
155
TD Private Client Wealth
New York
| – | -$13K | -210 | Closed |
|
156
Simplex Trading
Chicago,
Illinois
| – | -$10K | -162 | Closed |
|
|
CG
157
Cutler Group
San Francisco,
California
| – | -$3K | -51 | Closed |
|
|
TFA
158
Transamerica Financial Advisors
St. Petersburg,
Florida
| – | -$1K | -3 | Closed |
|
IHE Hedge Fund Activity: Q1 2024 in Review
143 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q1 2024, worth a combined $379M — down 10% from $422M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new IHE positions and 14 closed out — a net gain of 9 holders — while 32 added to existing stakes and 50 trimmed.
The largest buyer was Accurate Wealth Management, opening a new position worth an estimated $7.72M. The largest seller was Morgan Stanley, cutting an estimated $50.6M.
- 143 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q1 2024, up from 137 in Q4 2023.
- Funds reported $379M of iShares US Pharmaceuticals ETF stock for Q1 2024, down 10% quarter-over-quarter.
- 23 funds opened new iShares US Pharmaceuticals ETF positions in Q1 2024 and 14 closed out, a net change of +9 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q1 2024 was Accurate Wealth Management, an estimated $7.72M added.
- The largest iShares US Pharmaceuticals ETF seller in Q1 2024 was Morgan Stanley, an estimated $50.6M sold.
Based on aggregated 13F filings for Q1 2024.